Patents by Inventor Gou Young Koh
Gou Young Koh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230272057Abstract: The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention further provides an angiogenesis inhibitor and a composition for treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.Type: ApplicationFiled: October 12, 2022Publication date: August 31, 2023Applicants: Institute for Basic Science, Korea Advanced Institute of Science and TechnologyInventors: Gou Young Koh, Jeomil Bae, Mi Jeong Kim, Jin-Sung Park, Su Jin Seo, Jaeryung Kim, Jang Ryul Park, Pilhan Kim, Wangyuhl Oh
-
Patent number: 11498962Abstract: The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention further provides an angiogenesis inhibitor and a composition for treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.Type: GrantFiled: August 17, 2020Date of Patent: November 15, 2022Assignees: Institute for Basic Science, Korea Advanced Institute of Science and TechnologyInventors: Gou Young Koh, Jeomil Bae, Mi Jeong Kim, Jin-Sung Park, Su Jin Seo, Jaeryung Kim, Jang Ryul Park, Pilhan Kim, Wangyuhl Oh
-
Publication number: 20210179719Abstract: The present invention refers to an antibody against Tie-2 or antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a manufacturing method of the antibody or antigen-binding fragment thereof, and a composition for preventing or treating angiogenic diseases, which comprises the antibody or antigen-binding fragment thereof.Type: ApplicationFiled: December 3, 2020Publication date: June 17, 2021Applicants: INSTITUTE FOR BASIC SCIENCE, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Gou Young Koh, Jeomil Bae, Jaeryung Kim
-
Publication number: 20210079083Abstract: The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention provides an angiogenesis inhibitor and a composition for prevention and treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.Type: ApplicationFiled: August 17, 2020Publication date: March 18, 2021Applicants: INSTITUTE FOR BASIC SCIENCE, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Gou Young Koh, Jeomil Bae, Mi Jeong Kim, Jin-Sung Park, Su Jin Seo, Jaeryung Kim, Jang Ryul Park, Pilhan Kim, Wangyuhl Oh
-
Patent number: 10745472Abstract: The present invention relates to a composition which is for preventing and treating eye diseases and comprises an anti-angiopoietin-2 (Ang2) antibody and, more specifically, to a novel use of an anti-Ang2 antibody as an agent for preventing or treating eye diseases, wherein the anti-Ang2 antibody is specifically coupled to Ang2, is coupled to a Tie2 receptor together with Ang2, and has improved affinity. The composition according to the present invention can be usefully used to develop a treatment agent for macular degeneration, diabetic retinopathy, and glaucoma.Type: GrantFiled: December 19, 2017Date of Patent: August 18, 2020Assignees: INSTITUTE FOR BASIC SCIENCE, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Gou Young Koh, Jaeryung Kim, Do Young Park
-
Publication number: 20190330324Abstract: The present invention relates to a composition which is for preventing and treating eye diseases and comprises an anti-angiopoietin-2 (Ang2) antibody and, more specifically, to a novel use of an anti-Ang2 antibody as an agent for preventing or treating eye diseases, wherein the anti-Ang2 antibody is specifically coupled to Ang2, is coupled to a Tie2 receptor together with Ang2, and has improved affinity. The composition according to the present invention can be usefully used to develop a treatment agent for macular degeneration, diabetic retinopathy, and glaucoma.Type: ApplicationFiled: December 19, 2017Publication date: October 31, 2019Inventors: Gou Young KOH, Jaeryung KIM, Do Young PARK
-
Patent number: 10259860Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.Type: GrantFiled: October 31, 2007Date of Patent: April 16, 2019Assignee: APROGEN INC.Inventors: Hak-Zoo Kim, Young Jun Koh, Ho-Min Kim, Keehoon Jung, Choonjoo Jeon, Gou Young Koh
-
Patent number: 9777261Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.Type: GrantFiled: June 15, 2015Date of Patent: October 3, 2017Assignee: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Ho Min Kim, Jung-Eun Lee, Chan Kim, Gou Young Koh, Gyun Min Lee
-
Publication number: 20170156351Abstract: The present application describes a device that includes a packaging made of foldable stiff material, which is fastened to a fold-out drape.Type: ApplicationFiled: July 11, 2015Publication date: June 8, 2017Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hyeon-jeong SUK, Gou Young KOH, Jaemyung LEE, Kyeong Ah JEONG, Hyunjoo BAE, Sung Yong CHOI
-
Patent number: 9505841Abstract: A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.Type: GrantFiled: July 29, 2014Date of Patent: November 29, 2016Assignees: SAMSUNG ELECTRONICS CO., LTD., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Kyung Eun Kim, Sang Yeul Han, Gou Young Koh, Hyo Seon Lee, Chan Kim
-
Patent number: 9498516Abstract: Provided is a composition for preventing or treating erectile dysfunction including angiopoietin-4 protein as an active ingredient. Angiopoietin-4 protein increases an endothelial cell-specific protein level to induce regeneration of penile vascular endothelial cells, thereby increasing intracavernous pressure. Thus, angiopoietin-4 protein may be efficiently applied to prevention or treatment of erectile dysfunction.Type: GrantFiled: November 13, 2013Date of Patent: November 22, 2016Assignee: INHA INDUSTRY PARTNERSHIP INSTITUTEInventors: Jun Kyu Suh, Ji Kan Ryu, Mi Hye Kwon, Gou Young Koh
-
Publication number: 20160151451Abstract: The present application describes a method of creating cardioblasts and cardiomyocytes.Type: ApplicationFiled: November 27, 2014Publication date: June 2, 2016Inventors: Sung Woo CHO, Seon Pyo Hong, Sukhyun Song, Yong-Mahn Han, Gou Young Koh
-
Publication number: 20160032259Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.Type: ApplicationFiled: June 15, 2015Publication date: February 4, 2016Inventors: Ho Min KIM, Jung-Eun Lee, Chan Kim, Gou Young Koh, Gyun Min Lee
-
Publication number: 20150368617Abstract: The present application discloses a method of promoting differentiation and expansion of endothelial cells (EC) and cardiomyocytes from a pluripotent cell, which includes contacting the pluripotent cell with a Rho-associated protein kinase (ROCK) suppressor.Type: ApplicationFiled: May 7, 2014Publication date: December 24, 2015Applicant: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Gou Young KOH, Hyung Joon Joo, Dong Kyu Choi, Jin-Sung Park, Sung Woo Cho
-
Publication number: 20150183864Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.Type: ApplicationFiled: November 12, 2014Publication date: July 2, 2015Inventors: KEEHOON JUNG, YOUNG JUN KOH, GYUN MIN LEE, SUN CHANG KIM, GOU YOUNG KOH
-
Publication number: 20150079112Abstract: A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.Type: ApplicationFiled: July 29, 2014Publication date: March 19, 2015Inventors: Kyung Eun KIM, Sang Yeul Han, Gou Young Koh, Hyo Seon Lee, Chan Kim
-
Patent number: 8927232Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.Type: GrantFiled: December 11, 2009Date of Patent: January 6, 2015Assignee: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
-
Publication number: 20140370079Abstract: The present application describes a method of inhibiting tumor growth including contacting the tumor with a compound that inhibits activity of RhoJ protein.Type: ApplicationFiled: May 6, 2014Publication date: December 18, 2014Applicant: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Gou Young KOH, Chan Kim, Hanseul Yang, Won Do Heo, Injune Kim, Sangyong Jon, Akiyoshi Uemura
-
Publication number: 20140148385Abstract: Provided is a composition for preventing or treating erectile dysfunction including angiopoietin-4 protein as an active ingredient. Angiopoietin-4 protein increases an endothelial cell-specific protein level to induce regeneration of penile vascular endothelial cells, thereby increasing intracavernous pressure. Thus, angiopoietin-4 protein may be efficiently applied to prevention or treatment of erectile dysfunction.Type: ApplicationFiled: November 13, 2013Publication date: May 29, 2014Applicant: INHA INDUSTRY PARTNERSHIP INSTITUTEInventors: Jun Kyu SUH, Ji Kan RYU, Mi Hye KWON, Gou Young KOH
-
Patent number: 8414877Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.Type: GrantFiled: May 17, 2012Date of Patent: April 9, 2013Assignee: Aprogen, Inc.Inventors: Gou Young Koh, Chung-Hyun Cho